ABBV Net income
Net income at AbbVie fell to $4.2B in fiscal 2025, the lowest in the 5 years reported, from $4.3B in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 1551152 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | $4.2B | $-52M |
| FY2024 | $4.3B | $-585M |
| FY2023 | $4.9B | $-7.0B |
| FY2022 | $11.8B | +$294M |
| FY2021 | $11.5B | — |
Cross-checks touching this measure FROM THE FILING REVIEW
✓ CLEANCash conversion stability
OCF ÷ NI ran 4.50× · 4.39× · 4.69× across three years — swing 0.30×, inside the 1.00× threshold.
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Net income across coverage → · ABBV company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.